Four years after Omeros came up short in its bid to gain an FDA approval for stem cell transplant drug narsoplimab, the ...
The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea ...
It is the first evidence that MCL patients in complete remission, with undetectable minimal residual disease (MRD), may be able to rely on highly effective standard treatments and avoid the rigors of ...
MedPage Today on MSN
First Drug for Deadly Transplant Complication Gets FDA's Blessing
The FDA has approved narsoplimab (Yartemlea) as the first treatment for hematopoietic stem cell transplant (HSCT)-associated ...
A study reveals the gut microbiome's role in predicting multiple myeloma outcomes, highlighting butyrate-producing bacteria ...
Transplanted autologous corneal stem cells successfully repaired corneal injuries in patients. Over 90% of patients achieved complete or partial success. The procedure proved safe with no serious ...
Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...
Hematologists and oncologists from UC San Francisco shared research results and clinical guidance at the world’s premier meeting for malignant and non-malignant hematology at the American Society of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback